US-based Riparian Pharmaceuticals, Inc., a biotechnology company focused on cardiovascular diseases and co-incubated by Viva Biotech (HKG: 1873), has announced an exclusive license agreement and research agreement with US pharmaceutical giant Pfizer (NYSE: PFE). Under the terms of the agreement, Pfizer will receive exclusive rights to a Riparian preclinical program in exchange for upfront and milestone payments, as well as royalties on sales of any resulting therapeutics.
Supporting Riparian’s Vasoprotection Efforts
As part of the research agreement, Pfizer will provide support for Riparian’s ongoing efforts to discover further drug targets that lead to vasoprotection, a process aimed at protecting blood vessels from damage. Pfizer will also have an option on such targets, indicating a strategic commitment to advancing cardiovascular therapies.
Funding and Partnerships for Riparian Pharmaceuticals
Riparian Pharmaceuticals, a privately held biotech company dedicated to discovering drug targets and therapeutics that address endothelial dysfunction and vascular inflammation, has secured USD 6 million in combined investment and research services from Viva Biotech Incubator and JMCR Partners. Additionally, the company has received support from research foundations such as the National Institutes of Health and the Massachusetts Life Science Center, highlighting the significance of its work in the field of cardiovascular diseases.-Fineline Info & Tech
